Navigation Links
Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
Date:4/26/2012

PRINCETON, N.J., April 26, 2012 /PRNewswire/ -- Omthera Pharmaceuticals, Inc., a privately held specialty pharmaceuticals company, today announced positive top-line data from its EVOLVE (EpanoVa fOr Lowering Very High triglyceridEs) clinical study for Epanova™, the Company's lead compound for the treatment of patients with very high triglycerides.  The Phase 3 clinical trial randomized 399 subjects with triglyceride levels of 500-2000 mg/dl to 2, 3, or 4 grams of Epanova, or 4 grams of olive oil for a total of 12 weeks of treatment. The primary endpoint of the trial was the percentage change in triglyceride level from baseline to week 12, and the secondary endpoint was the reduction in non-HDL-cholesterol.  The top-line results demonstrated highly statistically significant reduction of triglycerides in all dose groups, with median decreases in triglycerides from baseline to end of treatment of approximately 26% in the 2 gram cohort and 31% for those subjects on the 4 gram dose.  Furthermore, Epanova appeared safe and well tolerated, with discontinuation rates due to adverse events, primarily gastrointestinal, ranging from 5% to 7% across all dosing groups.

Commenting on the results, Jerry Wisler, Chief Executive Officer and Co-Founder of Omthera, stated, "We are pleased by the comprehensive lipid benefits shown by Epanova in the EVOLVE study - especially at the 2 gram dose, which demonstrated triglyceride lowering comparable to that of 4 gram doses of other prescription omega-3 products.  This comparable efficacy of Epanova at a significantly lower dose supports the prior demonstration of improved bioavailability of this free fatty acid formulation versus the ethyl ester form found in other prescription Omega 3 products.  The preliminary data also showed dose-dependent increases in plasma EPA and DHA levels with Epanova.  We look forward to completing a comprehensive analysis of the study and aim to present t
'/>"/>

SOURCE Omthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omthera Pharmaceuticals, Inc. to Present at Leerink Swann 2012 Global Healthcare Conference and Citi 2012 Global Healthcare Conference
2. Omthera Pharmaceuticals Announces Positive Long Term Bioavailability Data Comparing Epanova™ to Lovaza®
3. Omthera Pharmaceuticals, Inc. to Present at the 30th Annual J.P. Morgan Healthcare Conference
4. Omthera Pharmaceuticals, Inc. to Present at the 23rd Annual Piper Jaffray Health Care Conference
5. Timothy J. Maines Joins Omthera Pharmaceuticals as Vice President of Quality
6. Omthera Pharmaceuticals, Inc. to Present at the Rodman and Renshaw 13th Annual Healthcare Conference
7. Omthera Pharmaceuticals, Inc. Initiates Phase III ESPRIT Trial of Add-on Epanova™ to Statin Therapy in Patients with Hypertriglyceridemia
8. Christian S. Schade to Join Omthera Pharmaceuticals as Executive Vice President and Chief Financial Officer
9. Drs. Ben Machielse Joins Omthera Pharmaceuticals, Inc. as Chief Operating Officer
10. Omthera Pharmaceuticals, Inc. to Present at the 2011 Wells Fargo Securities Healthcare Conference
11. Omthera Pharmaceuticals, Inc. to Present at the BIO Windhover/Pharmaceutical Strategic Outlook 2011 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... and NOTTINGHAM, England , ... CBRX ) today announced that its subsidiary, Molecular ... Clinical Trials platform at the annual CPhI/ICSE Worldwide event ... aims to support companies with the rapid development of ... new enabling technologies screening platform, which incorporates the company,s ...
(Date:10/1/2014)... and NEW YORK , October 1, ... Research Organization (CRO) and service provider for the medical industries, announced ... of offices in New York City . genae ... City is strategically centered in one of the highest ... Coast", said Philippe Kassab , President at genae Americas. "The ...
(Date:10/1/2014)... 1, 2014 Trovagene, Inc., (NASDAQ:  TROV) ... that Eli Diamond , MD, Assistant Attending ... presented clinical data from an ongoing study demonstrating ... for the determination of oncogene mutational status in ... results were presented to both treating physicians and ...
Breaking Medicine Technology:Columbia Laboratories' UK Subsidiary To Launch New Development Platform At CPHI 2Columbia Laboratories' UK Subsidiary To Launch New Development Platform At CPHI 3genae Opens Offices in New York City 2Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 2Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 3Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 4
... Roper Industries, Inc. (NYSE: ROP ) ... (CUSIP No. 776696AA4) (the "Notes") will accrue contingent interest for ... at an annual rate of 0.25% of the average market ... January 12, 2011. Contingent cash interest, which the Company has ...
... 18, 2011 Soligenix, Inc. (Soligenix or the ... a late-stage biopharmaceutical company, announced today promising preliminary ... beclomathasone dipropionate or BDP) in a canine gastrointestinal ... that dogs treated with SGX202 demonstrated statistically significant (p=0.04) ...
Cached Medicine Technology:Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury 2Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury 3Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury 4Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury 5
(Date:10/1/2014)... strongly associated with Alzheimer,s disease; however, researchers are still ... causal agent of the onset and development of the ... beta-amyloid is not harmful when found in isolation but ... to form the so-called amyloid fibrils , "We are ... with multiple ones because each aggregate of peptide, which ...
(Date:10/1/2014)... 1, 2014 Patients with increased inflammation, including ... greatly increased risk of depression. For example, a ... hepatitis C virus infection causes depression in approximately ... more commonly known as fish oil, have a ... risk of heart disease and reducing triglyceride levels. ...
(Date:10/1/2014)... October 01, 2014 Insuranceragents.info has ... a good life insurance plan for vulnerable family members. ... vulnerable family members. Providers in the family should always ... cause financial hardships for the rest of the family. ... policies. Families can benefit more from temporary coverage or ...
(Date:10/1/2014)... ATLANTA (PRWEB) October 01, 2014 ... executive networking and relationship-marketing firm, announced today ... Security Executive® and Project of the Year ... decision makers representing organizations in financial services, ... include large-scale technology endeavors that address key ...
(Date:10/1/2014)... 01, 2014 Between 23 million and ... U.S., according to figures from the National Institutes of ... (AARDA), and many of them have something else in ... undiagnosed celiac disease. Gluten Free Therapeutics, makers of ... undiagnosed celiac disease by publishing a series of blog ...
Breaking Medicine News(10 mins):Health News:Laying siege to beta-amyloid, the key protein in Alzheimer's disease 2Health News:Omega-3 fatty acids may prevent some forms of depression 2Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 3Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 4Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 5Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 6Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 7Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3
... , , , ... BMR ), The Leading Provider of Real Estate to the Life Science ... ring The Closing Bell(R) at the New York Stock Exchange on Thursday, ... anniversary of the company,s initial public offering. The ceremony will take place ...
... Tinnitus Sufferer ... ... of a deep-sleep to a high pitch ringing sound in your ear, or constantly hearing ... reality for millions of men and women who suffer from the medical condition tinnitus, often ...
... ... marketplace. , ... FL (PRWEB) August 6, 2009 -- Because prices and benefits for Medicare Supplement (Medigap) ... rates offered by GetOnlineQuotes.com are an affordable and viable option for those 65 and ...
... August 6, 2009 Comprehensive health reform proposals now before ... young adults ages 19-29 gain coverage, and such reforms ... coverage would not lose it, according to a new ... Americans through expansions in Medicaid and a health insurance ...
... Addison, TEXAS, Aug. 5 U L URU ... today announced that it has scheduled a conference call to discuss the second ... on Monday, August 17, 2009 at 9:00 a.m. Eastern Time. , , ... international callers dial (850) 429-1388 (access code 23453#) five to ten minutes prior ...
... , , MENLO PARK, Calif., ... announced that it has provided written notice to The NASDAQ Stock ... stock from the NASDAQ Global Market. The Company currently anticipates that, ... the Securities and Exchange Commission and NASDAQ a Form 25 relating ...
Cached Medicine News:Health News:BioMed Realty Trust Commemorates Five-Year Anniversary as a Public Company 2Health News:BioMed Realty Trust Commemorates Five-Year Anniversary as a Public Company 3Health News:BioMed Realty Trust Commemorates Five-Year Anniversary as a Public Company 4Health News:BioMed Realty Trust Commemorates Five-Year Anniversary as a Public Company 5Health News:BioMed Realty Trust Commemorates Five-Year Anniversary as a Public Company 6Health News:BioMed Realty Trust Commemorates Five-Year Anniversary as a Public Company 7Health News:Lipo-Flavonoid Launches New Video Testimonial 2Health News:Lipo-Flavonoid Launches New Video Testimonial 3Health News:GetOnlineQuotes.com to Offer AARP/United Healthcare Medicare Supplement Insurance to Florida Residents 2Health News:Health reform proposals could help 13 million uninsured young adults gain coverage 2Health News:Health reform proposals could help 13 million uninsured young adults gain coverage 3Health News:ULURU Inc. Announces Conference Call to Discuss Financial Results for the Second Quarter Ended June 30, 2009 and to Provide a Business Update 2Health News:XTENT Announces Plan for NASDAQ Delisting and Filing of Certificate of Dissolution 2
BB Watchmaker Forceps, Pakistan, 4.5" fine point....
The vertebral body replacement (VBR) is used for the anterior thoracic and lumbar spine. It is intended for use in the thoracic and lumbar spine to replace a collapsed, damaged, or unstable vertebral...
Vertigraft femoral shaft an large femoral cross-section designed primarily for use in lumbar corpectomy procedures. Freeze dried preservation....
... system provides anterior column support for single ... T1 to L5. The system consists of ... cages that are stacked to a desired ... Carbon fiber reinforced polymer material emulates the ...
Medicine Products: